{"id":"W4379383902","doi":"10.1177/17588359231175440","title":"Targeting HER2-low in metastatic breast cancer: an evolving treatment paradigm","year":2023,"lang":"en","type":"review","venue":"Therapeutic Advances in Medical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of British Columbia; BC Cancer Agency; Ottawa Hospital; Sinai Health System; University of Toronto; University of Alberta; University of Calgary","funders":"National Cancer Institute; Mylan; AstraZeneca Canada; Seagen; Gilead Sciences; Amgen; Pfizer; AstraZeneca; Eli Lilly and Company","keywords":"Medicine; Trastuzumab; Oncology; Breast cancer; Metastatic breast cancer; Internal medicine; Clinical trial; Biomarker; Disease; Hormone receptor; Pertuzumab; Cancer; Population; Human Epidermal Growth Factor Receptor 2","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001705392,0.0005937441,0.001762669,0.001528291,0.0002123554,0.001343416,0.001034332,0.00112377,0.002373081],"category_scores_gemma":[0.001256193,0.0002102604,0.0006036873,0.001461899,0.0005734015,0.001777895,0.0006777017,0.003059426,0.001227523],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007323913,"about_ca_system_score_gemma":0.001267811,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008113477,"about_ca_topic_score_gemma":0.00253649,"domain_scores_codex":[0.9997204,0.00009167896,0.00004114465,0.00004128596,0.00007972099,0.00002575118],"domain_scores_gemma":[0.9993255,0.00041999,0.00006687,0.00001375604,0.0001371064,0.00003683015],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0001282519,0.00007214268,0.0001270907,0.01661779,0.0001154375,0.000144638,0.00006019813,0.0004080052,0.000811387,0.007723448,0.01953699,0.9542545],"study_design_scores_gemma":[0.00007810249,0.0002672939,0.0005799297,0.01105877,0.0002136504,0.001067397,0.0001049815,0.0002175946,0.0003080709,0.004879908,0.9812024,0.00002186737],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.00007934044,0.9985709,0.00007308522,0.0007483986,0.0001029462,0.000003290408,0.000008336096,0.000003696588,0.0004098925],"genre_scores_gemma":[0.0005527016,0.9985531,0.0001301961,0.0004549303,0.0001278818,0.000004905492,0.00001298825,0.000001236747,0.0001621278],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.002373081,"threshold_uncertainty_score":0.009019077,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1399657081691481,"score_gpt":0.5367814479793399,"score_spread":0.3968157398101919,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}